Commentary on manuscript: Tigecycline for treating bloodstream infections: a critical analysis of the available evidence

Diagnostic Microbiology and Infectious Disease

Volumn 61, Issue 3, 2008, Pages 360-361

  Cobo, Javier ^a   Morosini, María Isabel ^a   Cantón, Rafael ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; TIGECYCLINE;

ANTIMICROBIAL ACTIVITY; BACTEREMIA; BACTERIAL MUTATION; BACTERIOSTASIS; BLOOD CLOT; DRUG BLOOD LEVEL; DRUG EFFICACY; ENDOCARDIUM; HOSPITAL; INTERNAL JUGULAR VEIN; KLEBSIELLA PNEUMONIAE; LETTER; MULTIDRUG RESISTANCE; OFF LABEL DRUG USE; PRIORITY JOURNAL; RESERVOIR; THROMBUS;

EID: 45349097205     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2008.01.026     Document Type: Letter

References (11)

1. Cobo J., Morosini M.I., Pintado V., Tato M., Samaranch N., Baquero F., and Cantón R. Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 β-lactamase-producing Klebsiella pneumoniae epidemic clone. Diagn. Microbiol. Infect. Dis. 60 (2008) 319-322
2. The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Steering Committee, EUCAST technical note on tigecycline. Clin. Microbiol. Infect. 12 (2006) 1147-1149
3. Fraise A.P. Tigecycline: the answer to β-lactam and fluoroquinolone resistance?. J. Infect. 53 (2006) 293-300
4. Hawkey P., and Finch R. Tigecycline: in vitro performance as a predictor of clinical efficacy. Clin. Microbiol. Infect. 13 (2007) 354-362
5. Lefort A., Lafaurie M., Massias L., Petegnief Y., Saleh-Mghir A., Muller-Serieys C., Le Guludec D., and Fantin B. Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis. Antimicrob. Agents Chemother. 47 (2003) 216-222
6. Livermore D.M. Introduction: the challenge of multiresistance. Int. J. Antimicrob. Agents 29 Suppl. 3 (2007) 1-7
7. Meagher A.K., Ambrose P.G., Grasela T.H., and Ellis-Grosse E.J. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin. Infect. Dis. 41 Suppl 5 (2005) S333-S340
8. Morosini M.I., García-Castillo M., Coque T.M., Valverde A., Novais A., Loza E., Baquero F., and Cantón R. Antimicrobial coresistance in extended-spectrum-β-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline. Antimicrob. Agents Chemother. 50 (2006) 2695-2699
9. Murphy T.M., Deitz J.M., Petersen P.J., Mikels S.M., and Weiss W.J. Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis. Antimicrob. Agents Chemother. 44 (2000) 3022-3027
10. Paterson D.L. Clinical experience with recently approved antimicrobials. Curr. Opin. Pharmacol. 6 (2006) 486-490
11. Rodvold K.A., Gotfried M.H., Cwik M., Korth-Bradley J.M., Dukart G., and Ellis-Grosses E.J. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J. Antimicrob. Chemother. 58 (2006) 1221-1229